Birchview Capital, LP

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed June 30, 2025), Birchview Capital, LP reported 59 stock positions worth $122.7 million. Its top holding was Bristol-Myers Squibb (BMY) at 31.1% of the portfolio, followed by Neurocrine Biosciences (NBIX, 8.7%) and Biodesix (BDSX, 6.2%). Compared with Q4 2023, it opened 2 new positions, sold out of 1, added to 7 and reduced 2. The biggest buy was Bristol-Myers Squibb (BMY, shares +0%) and the biggest sale an exit from Immunogen (IMGN).

Most Recent 13F
Q2 2026
Location
BURLINGTON, VT
CIK
0001618205
Portfolio Value
$122.7M (Q1 2024)
SEC Filing
0001618205-25-000005 ↗ filed Jun 30, 2025

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q1 2024: $122.7M $122.7M Q1 2024 Q2 2024: $108.2M Q2 2024 Q3 2024: $115.5M Q3 2024 Q4 2024: $122.9M Q4 2024 Q1 2025: $115.2M Q1 2025 Q2 2025: $100.7M Q2 2025 Q3 2025: $132.4M Q3 2025 Q4 2025: $170.8M Q4 2025 Q1 2026: $175.7M Q1 2026 Q2 2026: $213.8M Q2 2026

Holdings 59 stocks · $122.7M

BMY Bristol-Myers Squibb Co. 31.10% 703,606 $38.2M Add +0.2%
NBIX Neurocrine Biosciences Inc. 8.68% 77,240 $10.7M No change
BDSX Biodesix Inc. 6.22% 5,348,273 $7.6M No change
ELUT Elutia Inc. 4.25% 1,655,184 $5.2M No change
ACAD Acadia Pharmaceuticals Inc. 3.77% 250,400 $4.6M Add +4.2%
OVV Ovintiv Inc. 3.56% 84,200 $4.4M No change
PRTA Prothena Corp. PLC 3.42% 169,574 $4.2M No change
QDEL Quidelortho Corp. 2.55% 65,203 $3.1M No change
SILK Silk Road Medical Inc. filed as SILK RD MED INC 2.36% 158,094 $2.9M No change
STOK Stoke Therapeutics Inc. 2.31% 210,000 $2.8M No change
PHR Phreesia Inc. 2.24% 114,700 $2.7M No change
UTHR United Therapeutics Corp. 2.06% 11,000 $2.5M No change
MASI Masimo Corp. 1.83% 15,280 $2.2M No change
FHTX Foghorn Therapeutics Inc. 1.76% 320,930 $2.2M No change
HROW Harrow Inc. 1.62% 150,000 $2.0M No change
DCGO Docgo Inc. 1.51% 460,000 $1.9M Add +206.7%
INHIBRX INC 1.38% 48,448 $1.7M No change
ETRN Equitrans Midstream Corp. 1.35% 133,050 $1.7M No change
AXGN Axogen Inc. 1.14% 173,000 $1.4M No change
PTGX Protagonist Therapeutics Inc. 1.13% 48,000 $1.4M No change
ALKS Alkermes PLC 1.10% 50,000 $1.4M No change
CORT Corcept Therapeutics Inc. 1.03% 50,000 $1.3M No change
ATEC Alphatec Holdings Inc. 0.99% 88,000 $1.2M No change
TXG 10X Genomics Inc. Class A 0.92% 30,000 $1.1M No change
APLS Apellis Pharmaceuticals Inc. 0.86% 18,000 $1.1M No change
PXD Pioneer Natural Resources Co. 0.81% 3,800 $998K No change
TVTX Travere Therapeutics Inc. 0.77% 122,000 $941K No change
PGNY Progyny Inc. 0.68% 22,000 $839K No change
KPTI Karyopharm Therapeutics Inc. 0.58% 469,832 $709K No change
CYTK Cytokinetics Inc. 0.57% 10,000 $701K Reduce -60.0%
CHRS Coherus Oncology Inc. 0.53% 270,000 $645K Add +145.4%
ARVN Arvinas Inc. 0.50% 15,000 $619K No change
KNSA Kiniksa Pharmaceuticals Ltd. 0.48% 30,000 $592K No change
KALV Kalvista Pharmaceuticals Inc. 0.44% 46,000 $546K Add +15.0%
SWTX Springworks Therapeutics Inc. 0.40% 10,000 $492K No change
KROS Keros Therapeutics Inc. 0.38% 7,000 $463K No change
XENE Xenon Pharmaceuticals Inc. 0.35% 10,000 $431K No change
CGEM Cullinan Therapeutics Inc. 0.35% 25,114 $428K No change
BLUEBIRD BIO INC 0.34% 321,200 $411K No change
HALO Halozyme Therapeutics Inc. 0.33% 10,000 $407K No change
BIOHAVEN PHARMACEUTICAL HOLD 0.33% 7,365 $403K No change
GTHX G1 Therapeutics Inc. 0.28% 80,000 $346K No change
FOLD Amicus Therapeutics Inc. 0.27% 28,000 $330K No change
SRPT Sarepta Therapeutics Inc. 0.26% 2,500 $324K No change
ACCELERATE DIAGNOSTICS INC 0.26% 325,239 $322K Add +44.4%
AXSM Axsome Therapeutics Inc. 0.26% 4,000 $319K New
CSTL Castle Biosciences Inc. 0.25% 14,000 $310K Add +40.0%
XNCR Xencor Inc. 0.22% 12,300 $272K No change
ZNTL Zentalis Pharmaceuticals Inc. 0.21% 16,000 $252K No change
WVE Wave Life Sciences Ltd. 0.20% 40,000 $247K No change
CABA Cabaletta Bio Inc. 0.14% 10,000 $171K No change
GOSS Gossamer Bio Inc. 0.13% 138,176 $163K No change
VTYX Ventyx Biosciences Inc. 0.13% 28,800 $158K No change
LQDA Liquidia Corp. 0.12% 10,000 $148K Reduce -50.0%
TSVT 2SEVENTY Bio Inc. 0.09% 19,833 $106K No change
BCRX Biocryst Pharmaceuticals Inc. 0.08% 20,000 $102K No change
IFRX Inflarx NV 0.06% 50,000 $77K No change
CERO THERAPEUTICS HLDGS INC 0.03% 12,972 $40K New
YIELD10 BIOSCIENCE INC 0.01% 18,750 $7K No change

Portfolio Sells Q4 2023 → Q1 2024

IMGN Immunogen Inc. Sold out 0.00% −4.36
CYTK Cytokinetics Inc. Reduce -60.0% 0.57% −1.06
LQDA Liquidia Corp. Reduce -50.0% 0.12% −0.07

Portfolio Buys Q4 2023 → Q1 2024

BMY Bristol-Myers Squibb Co. Add +0.2% 31.10% +2.90
DCGO Docgo Inc. Add +206.7% 1.51% +0.86
AXSM Axsome Therapeutics Inc. New 0.26% +0.26
CHRS Coherus Oncology Inc. Add +145.4% 0.53% +0.24
CSTL Castle Biosciences Inc. Add +40.0% 0.25% +0.08
KALV Kalvista Pharmaceuticals Inc. Add +15.0% 0.44% +0.06
CERO THERAPEUTICS HLDGS INC New 0.03% +0.03
ACCELERATE DIAGNOSTICS INC Add +44.4% 0.26% −0.43
ACAD Acadia Pharmaceuticals Inc. Add +4.2% 3.77% −2.12

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 72$213.8MKLAC, BMY, LRCX, NTLA, SLDB
Q1 2026 73$175.7MKLAC, BMY, CMPX, LRCX, STOK
Q4 2025 68$170.8MKLAC, BMY, CMPX, STOK, LRCX
Q3 2025 69$132.4MKLAC, BMY, CORT, PRTA, STOK
Q2 2025 71$100.7MBMY, KLAC, CORT, OVV, ACAD
Q1 2025 68$115.2MBMY, CORT, ACAD, PRTA, BDSX
Q4 2024Amended 68$122.9MBMY, BDSX, ACAD, ELUT, PRTA
Q3 2024Amended 61$115.5MBMY, BDSX, ACAD, ELUT, UTHR
Q2 2024Amended 60$108.2MBMY, BDSX, ELUT, NBIX, SILK
Q1 2024Amended 59$122.7MBMY, NBIX, BDSX, ELUT, ACAD